LEXINGTON, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Aegis Conference to be held virtually on May 2-4, 2023.
Ms. Curley will present on Thursday, May 4, 2023, at 4:30 p.m. ET. To attend, please join here.
For more information about the conference, or to schedule a one-on-one meeting with iSpecimen’s management team, please contact your appropriate Aegis representative, or send an email to Aegis at This email address is being protected from spambots. You need JavaScript enabled to view it. or KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts
KCSA Strategic Communications
Raquel Cona / Michaela Fawcett
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.24 |
Daily Change: | -0.09 -6.44 |
Daily Volume: | 35,971 |
Market Cap: | US$1.190M |
January 16, 2025 December 20, 2024 December 13, 2024 December 12, 2024 November 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load